Astegolimab, a fully human monoclonal antibody developed by Genentech, though improved health status did not significantly reduce exacerbation rates over 48 weeks of treatment compared with placebo in patients with moderate to very severe COPD, revealed the latest COPD-ST2OP trial. The single-center, randomised, double-blind, placebo-controlled phase 2a trial, which evaluated 81 participants with COPD, found that the exacerbation rate was not significantly different between those assigned astegolimab and placebo. The  study conducted by researchers at the Institute for Lung Health of the National Institute for Health Research (NIHR) Leicester Biomedical Research Centre, UK, was published in The Lancet Respiratory Medicine.